Serum levels of angiopoietin-2 are associated with the growth of multiple myeloma
- 11 June 2013
- journal article
- research article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 31 (6) , 385-389
Abstract
Angiopoietins and their receptor, Tie-2, have crucial role in angiogenesis. We measured serum levels of angiopoietin-2 (Ang-2), soluble Tie-2, and factors of burden and prognosis in myeloma (LDH, CRP, beta-2 microglobulin, and interleukin-6) in 55 newly diagnosed patients, with 30 of them in plateau phase, in order to note correlations among them. Levels of Ang-2 were higher in patients in advanced stage of disease, decreased in plateau phase, and correlated with all other factors. Circulating Ang-2 in myeloma patients significantly correlated to factors of disease burden and prognosis, and therefore measuring its levels may be important for the valuation of the disease.Keywords
This publication has 30 references indexed in Scilit:
- Synergistic effect of vascular endothelial growth factor and angiopoietin-2 on progression free survival in multiple myelomaLeukemia Research, 2013
- Circulating angiopoietin‐1 to angiopoietin‐2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agentsInternational Journal of Cancer, 2011
- Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomibHaematologica, 2008
- VEGF Induces Tie2 Shedding via a Phosphoinositide 3-Kinase/Akt–Dependent Pathway to Modulate Tie2 SignalingArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Differential levels of soluble angiopoietin‐2 and Tie‐2 in patients with haematological malignanciesEuropean Journal of Haematology, 2006
- Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesisBlood, 2003
- Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: Correlation with markers of disease activityAmerican Journal of Hematology, 2003
- Moving disease biology from the laboratory to the clinicSeminars in Oncology, 2002
- Biomedical significance of endothelial cell specific growth factor, angiopoietinExperimental & Molecular Medicine, 2002
- Serum interleukin‐6 (IL‐6) and interleukin‐4 (IL‐4) in patients with multiple myeloma (MM)British Journal of Haematology, 1996